SecBot SecBot
PRESS-RELEASE ·Filed May 22, 2026

BNTX

BioNTech SE
NEUTRAL
Impact 5/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Monitor ASCO 2026 presentations (May 29–June 2) for detailed efficacy/safety data on pumitamig and gotistobart. Positive data could drive near-term upside for BNTX, but no regulatory or commercial milestones are imminent. Watch for analyst reactions and potential partnership updates.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$92.14
T+0 close · May 22, 2026 · via day close
Latest settled
+0.66%
T+60 · $92.75
Vs SPY
−2.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $92.14entry
  2. T+1 · 6mo ago +0.12%α −0.47% · $92.25
  3. T+5 · 6mo ago −0.48%α −2.14% · $91.70
  4. T+20 · 5mo ago −1.03%α +0.39% · $91.19
  5. T+60 · 3mo ago +0.66%α −2.53% · $92.75

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech announced new clinical data for pumitamig (Phase 2/3 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRESERVE-004 in platinum-resistant ovarian cancer) to be presented at ASCO 2026. The data show encouraging anti-tumor activity and durable overall survival, supporting the company's late-stage oncology pipeline of 25+ Phase 2/3 trials including 13 pivotal studies. No financial figures, guidance, or regulatory decisions were disclosed.

Key Facts

  • Pumitamig (PD-L1 × VEGF-A bispecific) interim Phase 2 data from ROSETTA Lung-02 in 1L NSCLC shows encouraging anti-tumor activity across PD-L1 levels; third global dataset to show consistent activity.
  • Gotistobart (anti-CTLA-4) Phase 2 PRESERVE-004 data in platinum-resistant ovarian cancer shows durable anti-tumor activity and clinically meaningful overall survival.
  • BioNTech has 25+ Phase 2/3 trials, including 13 ongoing pivotal trials and novel-novel combination trials with ADCs.
  • No revenue, EPS, guidance, or financial data were provided in the press release.
  • Presentations at ASCO 2026 (May 29–June 2) include two oral presentations and four trial-in-progress posters.

Financial Impact

No financial figures disclosed; pipeline updates are non-financial catalysts.

Risk Factors

  • Clinical data at ASCO may not meet expectations, leading to stock volatility.
  • No financial guidance or revenue catalysts provided; pipeline remains early-stage with execution risk.
  • Competition in NSCLC and ovarian cancer from established PD-1/CTLA-4 therapies and ADCs.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3299948

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20267d ago 6-K Neutral 4/10 Entry $87.21 Now $84.86 −2.69% settles Feb 8
  2. Nov 3, 202614d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202614d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202614d ago Press Release Neutral 5/10 Entry $86.92 Now $84.86 −2.37% settles Feb 1
  5. Oct 29, 202619d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $84.86 −4.79% settles Jan 27
  6. Oct 26, 202622d ago 6-K Bullish 5/10 Entry $86.86 Now $84.86 −2.30% settles Jan 22
  7. Oct 26, 202622d ago 6-K Bearish 5/10 Entry $86.86 Now $84.86 +2.30% settles Jan 22
  8. Oct 26, 202622d ago Press Release Bearish 6/10 Entry $86.86 Now $84.86 +2.30% settles Jan 22
  9. Oct 25, 202623d ago Press Release Bullish 6/10 Entry $86.86 Now $84.86 −2.30% settles Jan 22
  10. Oct 22, 202626d ago 6-K Neutral 5/10 Entry $89.67 Now $84.86 −5.36% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 22, 2026